Company: TXG
Filing Date: 2025-05-09
Form Type: 10-Q
Source: 0001770787-25-000032
Chunk: 0

Company: 10x Genomics, Inc.
Filing Date: 2025-05-09
Form: 10-Q
Item: Part I, Item 1
Chunk 0
---
Item 1.    Financial Statements.

10x Genomics, Inc.

Condensed Consolidated Balance Sheets

 (In thousands)

March 31,2025December 31,2024(Unaudited)(Note 1)AssetsCurrent assets:Cash and cash equivalents$377,061 $344,067 Marketable securities49,844 49,335 Accounts receivable, net52,549 87,862 Inventory74,710 83,107 Prepaid expenses and other current assets25,566 20,016 Total current assets579,730 584,387 Property and equipment, net246,087 252,648 Operating lease right-of-use assets55,577 57,290 Goodwill4,511 4,511 Intangible assets, net15,192 15,671 Other noncurrent assets2,296 4,129 Total assets$903,393 $918,636 Liabilities and stockholders’ equityCurrent liabilities:Accounts payable$10,068 $12,909 Accrued compensation and related benefits21,957 33,615 Accrued expenses and other current liabilities45,483 41,165 Deferred revenue20,949 20,658 Operating lease liabilities9,443 9,286 Total current liabilities107,900 117,633 Operating lease liabilities, noncurrent70,631 73,327 Deferred revenue, noncurrent12,569 12,513 Other noncurrent liabilities5,398 5,029 Total liabilities196,498 208,502 Commitments and contingencies (Note 4)Stockholders’ equity:Preferred stock— — Common stock2 2 Additional paid-in capital2,208,665 2,177,672 Accumulated deficit(1,501,405)(1,467,047)Accumulated other comprehensive loss(367)(493)Total stockholders’ equity706,895 710,134 Total liabilities and stockholders’ equity$903,393 $918,636  

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

3

Table of Contents

10x Genomics, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

(In thousands, except share and per share data)

Three Months EndedMarch 31,20252024Products and services revenue$137,823 $141,005 License and